Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

Two multicenter, single‐arm, single‐infusion, open‐label studies were conducted to evaluate the effect of ketoconazole (a strong CYP3A inhibitor) or rifampin (a strong CYP3A inducer) daily for 5 days on the pharmacokinetics (PK) and safety of romidepsin (8 mg/m(2) intravenous 4‐hour infusion for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Laille, Eric, Patel, Manish, Jones, Suzanne F., Burris, Howard A., Infante, Jeffrey, Lemech, Charlotte, Liu, Liangang, Arkenau, Hendrik‐Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034805/
https://www.ncbi.nlm.nih.gov/pubmed/26053962
http://dx.doi.org/10.1002/jcph.560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034805/
https://www.ncbi.nlm.nih.gov/pubmed/26053962
http://dx.doi.org/10.1002/jcph.560

Ejemplares similares